DSM will promote two new immune-health offerings at SupplySide West
DSM will highlight two of its latest introductions: a vitamin D ingredient called ampli-D and a micronutrient blend called Optimmunity.
DSM (Parsippany, NJ) will display a range of offerings at the upcoming SupplySide West trade show, taking place October 31 to November 4, 2022, in Las Vegas. At the show, the company will highlight two of its latest introductions in immune health: a vitamin D ingredient called ampli-D and a micronutrient blend called Optimmunity.
The company describes ampli-D as “an ingredient clinically proven to raise vitamin D levels more effectively than ordinary vitamin D to offer potent immune support.” Meanwhile, Optimmunity is “a curated micronutrient blend leveraging expert panel recommendations to bring effective, science-backed immune support to consumers faster.”
In addition to its new immune health rollouts, DSM will display its brain health ingredients, including its life’sOmega algae-based line. The company will also showcase its market-ready cannabidiol (CBD) ingredient blends with omega-3s and B vitamins. Digestive health is also a focus with the company’s probiotic, enzyme, and HMO ingredients. Early-life nutrition is a central theme, too, with DSM’s life’sDHA, Metafolin, and HMO products and blends. Finally, the company will discuss plant-based ingredients such as its high-purity plant-based protein isolate Vertis CanolaPro.
DSM’s SupplySide West Booth number is 4355.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
